

TES Bibliography

1. Argueta DA, Ventura CM et al. A balanced approach for cannabidiol use in chronic pain. *Front Pharmacol.* 2020; April 30;11:561.
2. Clinical Focus: Pain management - Original Research. 2020; Jan;132(1):56-61.
3. Eskander JP , Spall E, Spall A, Shah R, Kaye A. Cannabidiol (CBD) as a Treatment of Acute and Chronic Back Pain: A Case Se-ries and Literature Review May/Jun 2020;16(3):215-218.
4. Fede C, Pirri C, Petrelli L, Guidolin D, Fan C, De Caro R, Stecco C.Fede C, et al. Sensitivity of the Fasciae to the Endocanna-binoid System: Production of Hyaluronan-Rich Vesicles and Potential Peripheral Effects of Cannabinoids in Fascial Tissue. *Int J Mol Sci.* 2020 Apr 22;21(8):2936
5. Mecham, Carrillo-Salinas FJ et al. Perspectives on cannabis-based therapy of multiple sclerosis: a mini-review. *Frontiers in Cellular Neurosciences.* 2020; Feb; 14; 1-7.
6. Überall MA. A Review of Scientific Evidence for THC: CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. 2020 Feb 14;13:399-410.
7. Capano A. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: a prospective cohort study. *J Postgrad Med.* 2019; Nov;132:Pages 56-61.
8. Corroon J, Felice JF. The Endocannabinoid System and Its Modulation by Cannabidiol (CBD). *Altern Ther Health Med.* 2019; Jun;25(S2):6-14
9. Garantziotis S, Savani RC. Hyaluronan biology: A complex balancing act of structure, function, location and context. *Matrix Biol.* 2019 May; 78-79(1):1-10.
10. Harrison J VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils *Mayo Clin Proc.* 2019 Sep;94(9):1840-1851.
11. Kis B, Ifrim FC, Buda V, Avram S, Pavel IZ, Antal D, Paunescu V, Dehelean CA, Ardelean F, Diaconeasa Z, Soica C, Danciu C. Cannabidiol-from Plant to Human Body: A Promising Bioactive Molecule with Multi-Target Effects in Cancer. *Int J Mol Sci.* 2019 Nov 25;20(23):5905.
12. Piermarini C, Viswanath O. CBD as the New Medicine in the Pain Provider's Armamentarium . *Pain Ther.* 2019; 8:157–158
13. Slawek D, Meenrajan SR, Alois MR, Comstock Barker P, Estores IM, Cook R.J. Medical Cannabis for the Primary Care Physi-cian. *Prim Care Community Health.* 2019 Jan-Dec;10:21501327
14. Urits I, Borchart M, Hasegawa M, Kochanski J, Orhurhu V, Viswanath O. An update of current cannabis-based pharmaceuti-cals in pain medicine. *Pain and Therapy.* 2019.
15. VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils. *Mayo Clin Proc.* 2019 Sep;94(9):1840-1851
16. Wang J. Glial Endocannabinoid System in Pain Modulation. *Int J Neurosci.* 2019; Jan; 129(1):94-100
17. Watson JE, Kim JS, Das A., Watson JE, et al. Emerging class of omega-3 fatty acid endocannabinoids & their derivatives. *Prostaglandins Other Lipid Mediat.* 2019; Aug; 143:106337.

18. Wong H, Cairns BE. Cannabidiol, cannabinol and their combinations act as peripheral analgesics in a rat model of myofascial pain. *Arch Oral Biol*. 2019 Aug; 104():33-39.
19. Hilderbrand RL. Hemp & Cannabidiol: What is a Medicine? *Mo Med*. 2018 Jul-Aug;115(4):306-309.
20. Mouhamed Y, Vishnyakov A, Qorri B, et al. Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. *Drug Healthc Patient Saf*. 2018;10:45–66.
21. Watkins BA. Endocannabinoids, Exercise, Pain, and a Path to Health With Aging. *Mol Aspects Med*. 2018;Dec;64:68-78.
22. Zügel M, Maganaris CN, Wilke J, Hodges PW. Fascial tissue research in sports medicine: from molecules to tissue adaptation, injury and diagnostics: consensus statement. *Br J Sports Med*. 2018 Dec; 52(23):1497.
23. Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. *JAMA*. 2017;318(17):1708–9.
24. Devinsky O, Cross JH, Laux L, et al. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. *N Engl J Med*. 2017;376(21):2011-2020.
25. Hill KP, Palastro MD, Johnson B, Ditre JW. Cannabis and Pain: A Clinical Review. *Cannabis Cannabinoid Res*. 2017 May 1;2(1):96-104.
26. National Academies of Sciences, Engineering and M. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. *Natl Acad Press*. 2017.
27. Romero-Sandoval EA, Kolano AL, Alvarado-Vázquez PA. Cannabis and Cannabinoids for Chronic Pain. *Curr Rheumatol Rep*. 2017 Oct 5;19(11):67
28. Bosch-Bouju, Clémentine, and Sophie Layé. Dietary Omega-6/Omega-3 and Endocannabinoids: Implications for Brain Health and Diseases. *Cannabinoids in Health and Disease*. In Tech, 2016.
29. El Sohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC. Changes in Cannabis Potency over the Last Two Decades (1995-2014) - Analysis of Current Data in the United States. *Biol Psychiatry*. 2016;79(7):613-619.
30. Fede C, Albertin G, Stecco C, et al. Expression of the Endocannabinoid Receptors in Human Fascial Tissue. *Eur J Histochem*. 2016;Apr 11:60(2): 2642
31. Fede C, Albertin G, Petrelli L, Sfriso MM, Biz C, De Caro R, Stecco C. Expression of the endocannabinoid receptors in human fascial tissue. *Eur J Histochem*. 2016 Jun 28; 60(2):2643.
32. Litwiniuk M, Krejner A, Speyrer MS, Gauto AR, Grzela T. Hyaluronic Acid in Inflammation and Tissue Regeneration. *Wounds*. 2016 Mar; 28(3):78-88.
33. Maytin EV. Hyaluronan: More than just a wrinkle filler. *Glycobiology*. 2016 Jun; 26(6):553-9.
34. Russo EB. Clinical Endocannabinoid Deficiency Reconsidered: Current Research Supports the Theory in Migraine, Fibromyalgia, Irritable Bowel, and Other Treatment-Resistant Syndromes *Cannabis Cannabinoid Res*. 2016; 1(1): 154–165
35. Turcotte C, Blanchet MR et al. The CB2 receptor and its role as a regulator of inflammation. *Cellular and Molecular Life Sciences*. 2016; 73:4449-4470.
36. Walitt B, Klose P, Fitzcharles MA, Phillips T, Häuser W. Cochrane. Cannabinoids for fibromyalgia. *Database Syst Rev*. 2016 Jul 18;7(7):CD011694.

37. Cowman MK, Schmidt TA, Raghavan P, Stecco A. Viscoelastic Properties of Hyaluronan in Physiological Conditions. *Res.* 2015; 4():622.
38. Di Marzo V, Piscitelli F. The Endocannabinoid System and its modulating effects by phytocannabinoids. *Neurotherapeutics.* 2015; Oct;12(4):692-698.
39. Maccarrone M, Bab I, Bíró T, et al. Endocannabinoid signaling at the periphery: 50 years after THC. *Trends Pharmacol Sci.* 2015;36(5):277-296.
40. De Laurentiis A, Araujo HA, Rettori V. Role of the endocannabinoid system in the neuroendocrine responses to inflammation. *Curr Pharm Des.* 2014;20(29):4697-4706.
41. Hall W, Degenhardt L. The adverse health effects of chronic cannabis use. *Drug Test Anal.* 2014;6(1-2):39- 45.
42. McPartland JM, Guy GW, Di Marzo V. Care and Feeding of the Endocannabinoid System: A Systematic Review of Potential Clinical Interventions that Upregulate the Endocannabinoid System. Romanovsky AA, ed. *PLoS ONE.* 2014;9(3):e89566
43. Smith S, Wagner M. Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions. *Neuro Endocrinol Letters.* 2014;35(3):198-201.
44. Burston JJ, Sagar DR, Shao P, Bai M, King E, et al. Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Re-sponses Associated with Osteoarthritis of the Knee Joint. *PLoS ONE* 2013;8(11): e80440
45. Alger BE. Getting High on the Endocannabinoid System. *Cerebrum Dana Forum Brain Sci.* 2013.
46. Desai MJ, Saini V, Saini S. Myofascial pain syndrome: a treatment review. *Pain Ther.* 2013 Jun; 2(1):21-36.
47. Gupta S. Why I Changed My Mind on Weed. *CNN.*
<http://www.cnn.com/2013/08/08/health/gupta-changed- mind-marijuana/index.html>.
Published 2013
48. Pacher P, Kunos G. Modulating the endocannabinoid system in human health and disease: successes and failures. *The FEBS Journal.* 2013; 280(9), 1918–1943.
49. Hassanzadeh P, Hassanzadeh A (2012) The CB1 receptor-mediated endocannabinoid signaling and NGF: the novel targets of curcumin. *Neurochemical Research* 2012; 37: 1112–1120.
50. Bisset, Kathleen M., et al. The G protein-coupled cannabinoid-1 (CB 1) receptor of mammalian brain: inhibition by phthalate esters in vitro. *Neurochemistry International* 2011; 59.5: 706-713.
51. *Drugs of Abuse: A Dea Resource Guide.* Washington, D.C.: U.S. Dept. of Justice, Drug Enforcement Administration, 2011. Inter-net resource.
52. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. *Br J Clin Pharmacol.* 2011;72:5:735-744.
53. Russo EB. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol.* 2011;163(7):1344-1364.
54. Thors L, Burston JJ, Alter BJ, McKinney MK, Cravatt BF, et al. Biochanin A, a naturally occurring inhibitor of fatty acid amide hydrolase. *British Journal of Pharmacology.* 2010;160: 549–560.
55. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. *Cell* 2009;139: 267–284.

56. LANGEVIN, H. et al. Ultrasound evidence of altered lumbar connective tissue structure in human subjects with chronic LBP. 2009. BMC Musculoskeletal Disorders. 10:151-160.
57. Nagarkatti P, Pandey R, Rieder SA, Hegde VL, Nagarkatti M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem. 2009 Oct; 1(7):1333-49.
58. Pandey R, Mousawy K, Nagarkatti M, Nagarkatti P. Endocannabinoids and immune regulation. Pharmacological Research : The Official Journal of the Italian Pharmacological Society. 2009 60(2), 85–92.
59. Sandkuhler J. Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 2009; 89: 7
60. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008;20 Suppl 1:10-14.
61. McPartland JM. Expression of the Endocannabinoid System in Fibroblasts and the Myofascial Tissues. J Bodyw Mov Ther. 2008; April;12(2):169-182.
62. Kogan, N. M., Mechoulam, R. Cannabinoids in health and disease. Dialogues in Clinical Neuroscience. 2007. 9(4), 413–430.
63. Russo EB, Guy GW et al. Cannabis pain and sleep: lessons from therapeutic clinical trials of Sativex, a cannabis-based medicine. Chem Biodivers. 2007 Aug;4(8):1729-1743.
64. Fernandez-Ruiz J, Romero J et al. Cannabinoid CB2 receptor: a new target for controlling neural cell survival? Trends in Pharmacological Sciences. 2006; 28(1): 39-45.
65. McPartland JM, Matias I, Di Marzo V, Glass M. Evolutionary origins of the endocannabinoid system. Gene. 2006;370:64-74.
66. Schleip R. Fascial plasticity—A new neurobiological explanation: Part 1. J. Bodywork Mov. Ther. 2003;7:11–19.
67. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ. Cannabis use for chronic non-cancer pain: results of a prospective survey. Pain. 2003; Mar; 102(1-2):211-6.
68. Quistad, Gary B., et al. Cannabinoid CB1 receptor as a target for chlorpyrifos oxon and other organophosphorus pesticides. Toxicology letters 2002;135.1: 89-93.
69. Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science 2000;288: 1765–1769.
70. di Tomaso, Emmanuelle. Brain cannabinoids in chocolate. Nature 1996;382: 677-678.
71. NIH Drug Database: Dronabinol (Marinol, Synthetic THC).
<https://druginfo.nlm.nih.gov/drugportal/rn/1972-08-3>.
72. Pharmaceuticas G. Sativex (delta-9- tetrahydrocannabinol and cannabidiol).
<https://www.gwpharm.com/products-pipeline/sativex-delta-9-tetrahydrocannabinol-and-cannabidiol>.